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Objective: Spinal cord stimulator (SCS) implantation is used to treat chronic pain, includ-
ing painful musculoskeletal disorders (MSDs). This study examined the characteristics and
outcomes of veterans receiving SCSs in Veterans Health Administration (VHA) facilities.
Methods: The sample was drawn from the MSD Cohort and limited to three MSDs with the
highest number of implants (N=815,475). There were 1490 veterans with these conditions
who received SCS implants from 2000 to 2012, of which 95% (n=1414) had pain intensity
numeric rating scale (NRS) data both pre- and post-implant.
Results: Veterans who were 35–44 years old, White, and married reported higher pain NRS
ratings, had comorbid inclusion diagnoses, had no medical comorbidities, had a BMI
25–29.9, or had a depressive disorder diagnosis were more likely to receive an SCS.
Veterans 55+ years old or with an alcohol or substance use disorder were less likely to
receive an SCS. Over 90% of those receiving an SCS were prescribed opioids in the year
prior to implant. Veterans who had a presurgical pain score ≥4 had a clinically meaningful
decrease in their pain score in the year following their 90-day recovery period (Day 91–456)
greater than expected by chance alone. Similarly, there was a significant decrease in
the percent of veterans receiving opioid therapy (92.4% vs 86.6%, p<0.0001) and
a significant overall decrease in opioid dose [morphine equivalent dose per day (MEDD)
=26.48 vs MEDD=22.59, p<0.0003].
Conclusion: Results offer evidence of benefit for some veterans with the examined condi-
tions. Given known risks of opioid therapy, the reduction is an important potential benefit of
SCS implants.
Keywords: spinal cord stimulator, musculoskeletal disorders, veterans, outcomes, opioids
Introduction
The Veterans Health Administration (VHA) is the largest healthcare organization in
the United States, treating over 9 million veterans annually in recent years.1
Veterans are more likely than non-veterans to report pain and severe pain compared
to non-veterans.2 Estimates suggest that approximately 50% of male veterans, and
as many as 75% of female veterans, report pain when presenting to VHA primary
care settings.3,4 Painful musculoskeletal disorders (MSD) represent the largest
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cluster of medical conditions among veterans from the
Afghan and Iraqi wars.5 Since 2000, over 5 million veter-
ans receiving VHA care were diagnosed with one or more
MSDs; 25% of those were diagnosed with back
conditions.6
Since the 1960s, spinal cord stimulator (SCS) implan-
tation has been used to treat severe pain conditions, includ-
ing some MSDs. Since that time, there have been
numerous reports on the effectiveness of SCS implantation
as well as systematic reviews of the published
literature.7,13 Previous research, however, documents vari-
able effects of SCS implantation, particularly modest
effects in reducing pain intensity, with evidence of dissi-
pating effects over time. The large variation in SCS effi-
cacy has been attributed to poor patient selection.7,9,12,14,15
Although no nationally accepted guidelines exist to deter-
mine appropriate candidates for SCSs, the efficacy of
SCSs is better for patients with specific diagnoses (eg,
lumbar post-laminectomy syndrome, radiculopathy, poly-
neuropathy, complex regional pain syndrome, failed back
surgery, back pain, and limb pain).7,9,12,14,16,19
Furthermore, efficacy is higher after a successful SCS
trial, and also when patients are selected for permanent
implantation using stringent criteria (eg, using rule-outs
for specific psychological conditions such as somatization
and substance use disorders).9,12 Research also suggests
that SCS implants should be reserved for patients with
medically indicated conditions, who remain refractory to
more conservative pain management interventions, or who
are at particularly high risk of harm related to high dose
long-term opioid therapy.10,17,20 However, some new
research suggests that SCS implants may be useful to
manage chronic untreatable pain.21,23 Overall, there are
only limited samples that recent or large enough to study
outcomes such as reductions in: pain intensity ratings, use
and dosage of opioid therapy, improvement in functioning,
and/or improvement in quality of life ratings.19,24,32
Our aims in this study were to describe the demo-
graphic and clinical characteristics of veterans receiving
SCS implants in the VHA and their one-year post-implant
outcomes. We focused on SCS implants for three high
prevalence MSDs for which SCS may be indicated,
namely post-laminectomy syndrome of the lumbar region,
thoracic or lumbosacral neuritis or radiculitis, and lum-
bago. For these analyses, we compared veterans with these
three MSDs who either received an SCS implant or did not
during the observation period. For this cohort of veterans,
we examined changes in pain intensity ratings and changes
in opioid therapy receipt and dosing following SCS
implantation.
Methods
Creation of the MSD Cohort
TheMSD cohort is described in detail elsewhere.33 Briefly, it
was created to identify veterans with MSD diagnoses from
2000 to 2012.33 In order to be included in the MSD cohort,
veterans must have had at least two outpatient visits occur-
ring within 18 months of one another or one recorded inpa-
tient MSD diagnosis.34 The index date for entry into the
cohort was the date of the veteran’s first outpatient or inpa-
tient MSD diagnosis. A veteran could have more than one
MSD diagnosis on the index date. The MSD cohort was
approved by the Institutional Review Boards of the VA
Connecticut Healthcare System and the Yale School of
Medicine and was granted a HIPAA waiver and waiver of
informed consent.33
For veterans identified with an MSD, additional infor-
mation from other VHA electronic data sources was col-
lected, such as demographic characteristics (ie, age,
gender, race/ethnicity, and marital status) at or near the
index date. Veterans’ pain intensity numeric rating scale
(NRS) scores were collected from vital signs data recorded
in their electronic health records (EHRs). The NRS is used
in routine clinical care to screen for the presence and
intensity of pain by asking veterans, “On a scale of 0 to
10, where 0 means no pain and 10 means the worst
possible pain, what is your current pain level?” Pain
intensity ratings at MSD index date are the highest pain
intensity ratings collected on the index date. Pain intensity
ratings were categorized as none (0); mild (1,2,3); moder-
ate (4,5,6); or severe (7,8,9,10).35,36
Medical andmental health diagnoses were collected from
the EHR and considered comorbid with an MSD diagnosis if
they occurred up to one year prior to the MSD diagnosis or
up to six months after. All comorbid medical and mental
health conditions were collected in the same manner as MSD
diagnoses (ie, required two or more outpatient codes within
18 months, or one or more inpatient codes). The Charlson
Comorbidity Index (CCI) was calculated based on medical
diagnoses that were current in the year prior and up to six
months after theMSD index date.37 Higher scores on the CCI
suggest greater comorbidity, with patients who scored a 5 or
greater on the CCI at increased risk of mortality within
one year. Body Mass Index (BMI) was calculated using
height and weight at the time closest to the veteran’s entry
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into the MSD cohort. Mental health conditions examined in
the current study include: depressive disorders (ie, major
depressive disorder, depressive disorder NOS, dysthymia),
anxiety disorders (ie, anxiety disorder NOS, panic disorder,
generalized anxiety disorder, agoraphobia with and without
panic), post-traumatic stress disorder [PTSD]), serious men-
tal illness (SMI; bipolar disorder, schizophrenia, other psy-
chosis), alcohol use disorder, and drug use disorder. Drug and
alcohol use disorders were combined as substance use dis-
orders in multivariable models given their common negative
relationship with SCS implantation and small case size in the
SCS group. Pain intensity ratings and the Charlson
Comorbidity Index categories were collapsed due to small
sample sizes within the SCS implant group (for example,
minimal pain was combined with the no pain group).
Data on MSD cohort members were collected until the
end of 2012 to allow for follow-up. Demographic data,
except for marital status, were collected on the date of the
first MSD diagnosis. Marital status is the most current status
available at the time of the most recent cohort update.
Identification of SCS Implants and
Creation of the SCS Analytic Sample
Potential SCS implantations were identified using current
procedural terminology (CPT) codes of: 63,650 (lead
insertion), 63,655 (neuro-stimulator spinal procedure), or
63,658 (placement of a spinal neuro-stimulator) at any
VHA facility from January 2000 to December 2012.
Three diagnoses (post-laminectomy syndrome of the lum-
bar region, thoracic or lumbosacral neuritis or radiculitis,
and lumbago; ICD-9CM codes 724.2, 724.4 and 722.83)
accounted for 72.26% of SCS implants during this period.
An analytic sample was created as a subsample of the
MSD cohort, including persons with at least one of those
three diagnoses regardless of implant status (n=815,475).
This subsample allowed comparison of veterans with simi-
lar diagnoses who either did or did not receive an SCS
implant. Of the 815,475 veterans with one or more of the
conditions of interest, there were 1490 (0.18%) veterans
with one of these diagnoses who received an SCS implant.
To validate these codes, two members of the research team
(LDW and CMC) reviewed the procedure descriptions for
each veteran in the VHA surgical tables. Procedures
labeled “placement of a permanent SCS,” “stage or
Phase II SCS,” “dorsal column stimulator,” “spinal neuro-
modular implant,” “completion of a laminectomy,” “inser-
tion or replacement of an SCS,” or “implantable pulse
generator (IPG)” were included as SCS procedures. The
date of the veteran’s first SCS was recorded. If it could be
determined that a veteran had a trial SCS and a permanent
SCS implanted, the recorded date was the date of receiving
his/her first permanent SCS.
Independent Variables of Interest:
Veteran-Level Data Associated with
Implant and Follow-Up Outcomes
We examined pain intensity ratings and opioid therapy in
the year prior to SCS as predictors of SCS implantation and
changes in these measures as outcomes of implantation. Pain
intensity ratings prior to implant were operationalized as the
mean of all pain intensity ratings reported in the year prior to
receiving an SCS implant. Mean pain intensity ratings were
also calculated for the 90-day period following implant and
the period 91–456 days following implant (one year follow-
ing the post-SCS 90-day recovery period). VHA pharmacy
data on all opioid prescription dispensed in the year prior to
receiving an SCS implant were extracted. Opioid doses were
standardized to a morphine equivalency (MEQ) using estab-
lished weighting factors.38,39 Buprenorphine and methadone
were excluded, since they are used primarily in the treatment
of opioid use disorder. Using the same time-periods as for
average pain intensity, morphine equivalent doses per day (or
MEDDs) were calculated for three time periods: the year
prior to implant, 90 days post-SCS implant, and the year
following the post-SCS 90-day recovery period (Day
91–456). There were no missing data on opioids; there
were 76 pain intensity ratings missing (N for analyses with
pain intensity ratings =1414).
Statistical Analyses
Descriptive statistics were used to examine demographic
and clinical characteristics between the SCS-implant and
no-implant groups. Chi-square and t-tests were used to test
between-group differences. The association of SCS
implantation with demographic and clinical characteristics
selected based upon their association with pain and/or
being contraindications for SCS from the literature was
examined using logistic regression. Finally, to look at
clinically meaningful changes in both pain intensity rat-
ings and opioid prescription (at least 20%, 30%, and 50%
for each outcome) among those with SCS implantation, we
used a chi-square test. The timeframe of the SCS implant
also was examined in multinomial models containing the
three individual diagnoses. Outcomes were no change
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(reference group), decrease, and increase in pain intensity
ratings and in separate multinomial models no change
(reference group), decrease, and increase in MEDDs. In
order to examine clinically meaningful changes in these
outcomes, cutoffs for meaningful differences were estab-
lished as ≥20%, ≥30% and ≥50% change.
Results
Characteristics of Veterans Receiving SCS
Implants
There were 815,475 veterans with any of the three condi-
tions examined. In this analytic sample, there were 1490
veterans (0.2%) who received SCS implants for lumbago,
post-laminectomy syndrome of the lumbar region, or thor-
acic or lumbosacral neuritis or radiculitis between 2000
and 2012. Less than 30 veterans received SCS implants in
the first year examined (2000), but the number of implants
increased over time, peaking in 2011 (n = 217).
Table 1 compares the demographic and clinical char-
acteristics of those veterans who received SCS implants
versus those who did not. Those receiving SCS implants
were more likely to be White, under the age of 55 years,
and married; differences were all significant at p<0.0001.
There were several important differences between groups
in pain intensity ratings and comorbidity measures. The
pain intensity ratings on the MSD index date were signifi-
cantly higher among veterans who received SCS implants
(Categorical pain intensity 0–10 Chi-square test, chi-
square= 133.4, 3 df, p< 0.0001). In the year prior to SCS
implantation, 77.4% of veterans had pain intensity ratings
in the moderate or severe category (data not shown). The
pain intensity ratings at MSD baseline and the year prior to
SCS implantation were significantly correlated (Spearman
correlation=0.2, p<0.0001) (Data not shown). There was
a large percentage of veterans for whom pain intensity
ratings were missing (28%). This was also observed in
the larger MSD cohort and is likely to be the case for older
dates of service as the proportion of veterans missing pain
intensity ratings has decreased over time.33
Veterans with depressive disorders were more likely to
receive an SCS implant than veterans with alcohol and/or
drug use disorders. Veterans with higher Charlson
Comorbidity Index (CCI) scores were less likely to receive
an SCS implant than those with lower CCI scores.
Seventy-two percent of veterans with one or more CCI
comorbid condition received an SCS implant compared to
81% of veterans without comorbidities (chi-square
test=65.1, 3 df, p<0.0001). Those who were normal or
underweight were less likely to receive an implant (Chi-
square test = 13.6, 2 df, p=0.02). Anxiety disorders, PTSD
and SMI, were not significantly related to SCS implant.
Most veterans (92.3%) who received an implant were
prescribed opioids during the year prior to that surgery,
with a median MEDD of 26.5 mg.
In logistic models adjusting for demographic and clinical
characteristics (Table 2), findings remained similar; there
was a significantly increased odds for SCS implantation in
the 35–44 age group and a significantly decreased odds in the
55+ group compared to the under 35-year-old veterans.
Veterans with either moderate or severe pain intensity ratings
were more than twice as likely to receive an SCS implant
than those with mild pain intensity ratings. The multivariable
model revealed that veterans with one or more Charlson
comorbid conditions had lower odds of receiving an SCS
implant, with the higher comorbidity group failing to reach
statistical significance. These two categories were collapsed
and the comparison was made between any veterans with any
comorbidity and those with no comorbid conditions. The
number of MSD diagnoses was not a significant predictor
of SCS implant and was removed from the final model.
Examining the Odds of an SCS Implant by
Inclusion of Diagnosis
Three MSDs were included in the SCS analytic sample
(“inclusion diagnoses,” see Methods); these diagnoses
(post-laminectomy syndrome of the lumbar region, thor-
acic or lumbosacral neuritis or radiculitis, and lumbago)
were examined individually to determine the contribu-
tion of each group to the SCS outcomes. The disorders
are not mutually exclusive (7% of the analytic sample
and 47% of the veterans who had an SCS implant had at
least 2 MSD inclusion diagnoses). For each of the inclu-
sion diagnoses, there was overinclusion in the SCS sam-
ple for veterans with more than one diagnosis. Veterans
with a diagnosis of lumbago (either alone or concurrent
with one of the other inclusion diagnoses) comprised
96.2% of the analytic sample and 93.6% of the sample
receiving SCS. However, among those veterans receiving
an implant, only 47.4% had a diagnosis of lumbago
alone. Similarly, veterans with post-laminectomy syn-
drome of the lumbar region (either alone or concurrent
with at least one other inclusion diagnosis) accounted for
only 1.2% of the analytic sample but comprised 25.0%
of the veterans receiving implants. Veterans with
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thoracic or lumbosacral neuritis or radiculitis (alone or
concurrent with one of the other two diagnoses) exam-
ined accounted for 9.7% of the analytic sample and
41.2% of implants.
In our full logistic regression models with SCS implant
as the outcome, the odds ratio of receiving an SCS for
post-laminectomy syndrome of the lumbar region was
very high (OR=17.6, 95% CI 14.9, 20.8), followed by
thoracic or lumbosacral neuritis or radiculitis (OR=5.2,
95% CI 4.5, 6.0), and for lumbago (OR=2.0, 1.5, 2.6).
There were significant differences in baseline pain
intensity ratings among the diagnostic groups in the ana-
lytic sample (Baseline mean pain intensity ratings=4.04,
ANOVA, Chi-square (6 df) = 329.21, p<0.0001) with all
post-laminectomy groups (ie, those with post-laminectomy
alone or concurrent with one or more of the inclusion
diagnoses) having higher pain intensity ratings. This
same pattern was observed in the implant subsample but
did not reach statistical significance (Baseline mean
pain=5.25, ANOVA, Chi-square (6 df), F=1.67, p=0.1249).
Examining SCS by Time as the
Intervention Has Changed Over Time
The nature of SCS technology has changed over time, and
there is a widely held belief that the effectiveness of the
approach has improved. To investigate if SCS outcomes
have improved, a dichotomous variable was created (SCS
implant date ≤ 2006, SCS implant date > 2006). The choice
of 2006 as the cut-off point was based on expert opinion on
the lag time for VHA integration of new procedures.
Roughly one-quarter of spinal cord implants (N=407,
27.3%) were conducted before or during 2006. The early
and later implant groups differed on four characteristics: the
later implant group contained larger proportions of Black
veterans (10.7% vs 5.16%, p<0.0129), higher pain intensity
ratings pre-implant (p<0.0001) but not at baseline, veterans
with PTSD (14.22% vs 9.09%, p<0.0083), and differences in
the proportion of the specific diagnoses that comprised the
sample (Chi-square, 6 df =32.58, p<0.0001).
Clinical Outcomes
Pain Intensity
Collected at the time of entry into the cohort, the average
baseline pain intensity rating of veterans who went on to
have an SCS was significantly higher than those who did not
(Kruskal–Wallis test conclusions same as t-test; Chi-square
=114.57, 1 df, p<0.0001). Examining the pain rating closest
to the implant among veterans receiving one (“pre-implant”)
, the average pre-implant pain intensity rating was 5.16± 1.7
(mean±SD, n=1481). Pain intensity ratings were higher in
the 90-day post-operative period than pre-implant [average
rating=5.29±2.2 (mean±SD), sign test M=65.5, P<0.0005].
In the year following the post-operative period (Days
91–456), the average pain intensity rating was 5.11±2.1.
There was no statistically significant difference in the
pain intensity rating in the year following the 90-day post-
operative period (Days 91–456) compared to the pre-implant
rating (sign test, M=14.5, p<0.45). Changes in pre- to post-
SCS pain intensity ratings in Days 91–456 of ≥20%, ≥30%,
and ≥50% were used as thresholds for identifying clinically
meaningful improvements in pain intensity.40 Low propor-
tions of veterans had clinically meaningful decreases in pain
Table 1 Bivariate Analysis of Implant Status and Demographic
Characteristics in MSD Cohort Members with at Least One of
These 3 Diagnoses (Post-Laminectomy Syndrome of the Lumbar
Region, Thoracic or Lumbosacral Neuritis or Radiculitis, and
Lumbago)
No Implant SCS Implant
N (%) N (%) p-value
All 813,985 (100) 1490 (100)
Gender* 0.3855
Female 59,161 7.27 117 7.85
Male 754,824 92.73 1373 92.15
Age (DOB*) <0.0001
Under 35 87,180 10.71 182 12.21
35–44 115,151 14.15 341 22.89
45–54 230,556 28.32 507 34.03
55–64 210,655 25.88 337 22.62
65+ 170,443 20.94 123 8.26
Race/Ethnicity * <0.0001
White 572,227 70.30 1230 82.55
Black 146,744 18.03 137 9.19
Hispanic 47,430 5.83 74 4.97
Other 22,305 2.71 28 1.88
Unknown 25,549 3.14 1 1.41
Marital Status** <0.0001
Married 433,632 53.27 1004 67.38
Unmarried 136,836 16.81 134 8.99
Divorced/Other 143,517 29.92 352 23.62
Notes: *On date of entry into the cohort; **Most recent status.
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intensity (27.0%, 18.8%, and 9.3% for ≥20%, ≥30% and
≥50%, respectively) (Figure 1 illustrates changes in pain
intensity where a clinically meaningful change was set at
≥30% change; we see a small proportion of post-SCS veter-
ans had a meaningful decrease in pain in the year following
the 90-day recovery period.
Inclusion diagnosis did not differentially impact changes
in pain intensity ratings (Chi-square (6 df) =11.00, p=0.0855)
or in MEDDs (Chi-square (6 df) =10.07, p=0.1217) among
those who had an SCS implant. However, the level of pre-
implant pain did impact changes. Stratification of pain inten-
sity groups (mild, moderate, severe; 5 persons removed for
“no pain”) revealed significant differences in pain changes
across pre-implant severity groups at each clinical cutoff
point (≥20%, ≥30%, ≥50%) after implant. It is important to
note that large proportions of patients with mild pain showed
significant increases in their pain ratings after implant (range
32.9155.27% of patients). In patients who had pain (≥4) prior
to their SCS implant (N=1098), more had a clinically mean-
ingful decrease in their pain score in the year following their
90-day recovery period (Day 91–456) than expected by
chance alone (t-test −4.39, p<0.0001). We had set
a clinically meaningful change to be ≥30%.
SCS implants after 2006 were associated with
a significantly lower odds of substantial increases in pain
intensity ratings in the year following the post-SCS 90-day
recovery period (Definitions of substantial increase: ≥30%
pain increase OR=0.66, 95% CI: 0.49–0.90, p<0.0077; and
≥50% OR=0.60, 95% CI: 0.42–0.86, p<0.0057). While the
estimates and significance of implant timeframe remained
significant with inclusion diagnoses, age, race/ethnicity, and
PTSD in the models, they changed and became nonsignifi-
cant once pre-implant pain intensity rating was added to the
multinomial model.
Opioid Therapy
As previously noted, 92.4% of veterans receiving an SCS
implant were prescribed opioids during the year prior to
implant. The median MEDD was 26.48mg (Interquartile
range: 1st quartile 6.58, 3rd quartile 70.14 mg). In the 90-
day post-operative period, the proportion remained the same
(92.3%) as did the median MEDD (28.03 mg, Interquartile
range 1st quarter: 7.50, 3rd quarter: 73.56 mg). However, the
proportion of veterans dispensed any opioids significantly
decreased from 92% to 86.6% in the year following the 90-
day post-operative window compared to the year prior to
Table 2 Bivariate Analysis of Implant Status and Clinical




N (%) N (%)




No Pain 178,508 30.39 149 16.59
Minimal 81,022 13.79 76 8.46
Moderate 158,589 27.00 326 36.30




Underweight 4825 0.63 7 0.53
Normal 148,576 19.53 211 15.90
Overweight 293,853 38.62 560 42.20






1 649,071 79.74 1197 80.34
2 137,101 16.84 240 16.11





0 582,231 71.53 1205 80.87
1 147,816 18.16 194 13.02
2 45,885 5.64 47 3.15









52,832 6.49 87 5.84 0.3077
Alcohol Use
Disorder
70,458 8.66 79 5.30 <0.0001
Drug Use
Disorder
40,881 5.02 42 2.82 <0.0001
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implant (Chi-square=163.30, 1df, p<0.0001). The median
MEDD in the year after the 90-day post-operative period
was 22.59 mg (Interquartile range 1st quarter: 3.62, 3rd
quarter: 64.90 mg), a reduction of 0.49 mg from the pre-
implant dosage (Sign test M = −68.5, p<0.0003; Interquartile
range 1st quarter: −12.74, 3rd quarter: 8.75). When pre-
specified clinically meaningful decreases in MEDD were
examined, moderate proportions of veterans reached these
thresholds (41.41%, 36.71%, and 28.05% for ≥20%, ≥30%
and ≥50%, respectively) (Figure 2 illustrates changes in
MEDD where a clinically meaningful change was set at
≥20% change).
The odds of being prescribed opioids in the year follow-
ing the 90-day post-operative period was significantly higher
for those who had been prescribed opioids during the year
prior to their implant than those who had not (89.83% vs
47.37%, Chi-square test=163.30, 1 df, p<0.0001). A total of
200 veterans who had received an implant had no opioids
dispensed to them after their post-operative period.
Stratification of the pre-implant pain group (mild, mod-
erate, severe; 3 persons removed for “no pain”) revealed no
significant differences in opioid changes between pre-
implant severity groups at each clinical cutoff point (≥20%,
≥30%, ≥50%) after implant. Later implants (>2006) were
associated with significantly lower odds of substantial
MEDD increases in that year (Definitions of substantial
increase: ≥20% MEDD increase OR=0.59, 95% CI: 0.42–-
0.80, p<0.0006; ≥30% MEDD increase OR=0.63, 95% CI:
0.48–0.84, p<0.0017; ≥50%MEDD increase OR=0.57, 95%
CI: 0.43–0.75, p<0.0001). When age, race/ethnicity, PTSD
and pre-implant pain rating were added to these models, the
estimates and significance of timeframe of implant remained
significant. Having an implant after 2006 was associated
with significantly lower odds of MEDD increases (≥20%,
≥30% and ≥50%). There were no significant associations
between the timeframe of implant and decreases in pain or
MEDDs at any of the clinically meaningful ranges.
Discussion
SCS implants are one option for the management of refrac-
tory chronic pain. For many years, the VHA has been
performing these implants to help manage veterans’ pain.
This is the first study, however, to examine the characteris-
tics of veterans who have received SCS implants as well as
the outcomes associated with this therapy.
Consistent with the guidelines and recommendations for
the conservative use of SCS for chronic pain, between 2000
and 2012, only a small percentage of veterans with MSD
received an SCS in VHA settings. For that reason, the SCS
analytic sample was a subset of veterans with any of three
diagnoses with relatively high rates of SCS implantation (per
our MSD data), accounting for over 72% of all SCS implants
in the period of observation. The findings from this study are
consistent with the relatively small number of SCSs
implanted worldwide compared to the prevalence estimates
of chronic pain. The increasing number of SCSs implanted
through 2011 is likely consistent with VHA’s National Pain









Pain increased >30% Not clinically meaningful
change
Pain decreased >30%
Figure 1 Proportions of veterans in each pain intensity rating change category.
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Management and other efforts to promote access to advanced
pain medicine diagnostics and interventions.41 It is important
to note that VHA facilities that lack the capacity to perform
SCSs may authorize receipt of an implant at another VHA
facility or a non-VHA facility. Implants obtained outside
VHA are not captured in this study.
The current study describes the demographic and clin-
ical characteristics of veterans who received SCS implants
in VHA settings during the study period. Among the three
diagnoses examined, the likelihood of receiving an SCS
particularly increased with diagnoses of either post-
laminectomy syndrome of the lumbar region and/or thor-
acic or lumbosacral neuritis or radiculitis. Many veterans
had more than one MSD inclusion diagnosis which
increased their odds for an SCS implant. This suggests
more serious and/or complex cases were more likely to get
this more invasive treatment option. In particular, all post-
laminectomy groups had high rates of SCS implants, rela-
tive to their inclusion rate in the analytic sample.
White, aged 35–44 years, and married veterans with the
selected diagnoses of interest had greater odds of receiving
an SCS implant. It is possible that the difference in SCS
implant receipt reflects an age- or race-related difference in
access to this pain management treatment.42 An alternative
explanation for the observed age difference is that older
veterans may have received an SCS implant prior to the
starting date of the MSD cohort, and, as a result, would be
less likely to need an SCS during the study time period.
Younger veterans also may have been in better health and/
or more willing to accept newer technology or surgical
interventions. Race differences could reflect differences in
veteran preferences or potentially provider bias.
Veterans in receipt of SCS implants were more likely to
have higher pain intensity ratings at the time of their diag-
nosed MSD than those who did not receive this therapy. In
persons who had actionable pain (≥4) prior to their SCS
implant, participants had a clinically meaningful decrease
in their pain score in the year following their 90-day recovery
period. Lower rates of medical comorbidity and substance
use disorders among those receiving SCS implants are con-
sistent with the contraindications for SCS use.12 Previous
research suggests that the presence of mood and anxiety
disorders or PTSD is not a contraindication for
implantation.43,45 This prior research is important because
mood and anxiety disorders are known to be particularly
prevalent among individuals with chronic pain and may be
associated with heightened pain intensity, increased likeli-
hood of receiving opioid therapy, and greater overall
distress.46,48 In fact, this study suggests that veterans with
complex chronic pain marked by comorbid depressive dis-
order are more likely to receive SCS implants than those
without this disorder. It may be that providers’ recommenda-
tions for SCSs reflect their efforts to address the heightened
distress and suffering of veterans with painful MSDs. As
expected, given that presence of active substance use disor-
ders is a relative contraindication for many medical proce-
dures, the presence of these disorders was associated with
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Figure 2 Proportions of veterans in each change category for morphine equivalent daily dose.
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Ninety-two percent of veterans receiving SCS implants
received opioid therapy in the year prior to implantation,
and they had a median pain intensity rating in the moder-
ate or severe range. These data may suggest that veterans
who were considered for SCS implantation were among
those whose pain was not optimally managed despite
opioid therapy. There was a significant decrease in
the percent of veterans receiving opioid therapy and
a significant overall decrease in opioid dose. The results
offer evidence of benefit for some veterans with the tar-
geted conditions in the year following receipt of SCS
therapy. Given the risks associated with opioids,
a reduction in prescribed opioids is an important benefit
of SCS implants. Of course, SCS is not without risks and
is relatively expensive and invasive. A limitation of our
study is the lack of available data in the EHR regarding
physical and emotional functioning and quality of life.
Future research that examines these important veteran-
centered outcomes (eg pain-related interference) is encour-
aged to determine if it is a better indicator of positive
outcomes among veterans who have had an SCS.
Serious concerns have been raised about the escalating
rates of adverse health consequences from long-term
opioid therapy, including overdose and death.49,50 For
more than a decade, the VHA has promoted policy, evi-
dence-based guidelines, and quality improvement initia-
tives to address this concern.51 Thus, it is particularly
important for veterans with chronic pain to have access
to additional pain management strategies, such as SCSs,
that can help manage pain. Further research is needed to
understand the effect of SCS implantation on pharmacolo-
gical treatments for pain.
Strengths, Limitations, and Future
Directions
This study has multiple strengths. First, the availability of
comprehensive EHR and administrative data allowed many
variables to be analyzed to better describe veterans receiving
SCS implants. Second, the comprehensive EHR enabled the
examination of two particularly important veterans’ outcomes,
namely pain intensity ratings and opioid dosage outcomes
from pre- to post-SCS implant. Third, this is the only known
study focused on veterans, a particularly vulnerable subgroup,
who received SCS implants within the VHA.46 The subset was
limited to the three diagnoses most associated with receipt of
an SCS implant; this limitation precludes our ability to gen-
eralize to all veterans receiving SCS implants. This
information can inform the VHA’s leadership about its use of
this pain management approach as well as shape future public
policy about the use of SCS implants. Although there are
many important differences between the VHA and other inte-
grated healthcare systems – and especially private, fee-for-
service healthcare settings – given the paucity of large epide-
miologic observational studies of SCSs, the results of the
present study may have broader implications for non-VHA
care of veterans and civilians, as well.
There also are limitations to this study. First, because this
is a retrospective study, only variables that were readily
available in the EHR were examined. Pain intensity ratings
and opioids are currently the only two pain-relevant mea-
sures that were available from clinical data. Additional
demographic or clinical characteristics about the veteran
such as pain duration and pain interference were not avail-
able. Second, additional outcome variables (eg, disability
variables, work status, and quality of life) could not be
examined in this study because the data were not collected
in the EHR. Third, because this study only examined veter-
ans with SCSs who were members of the MSD cohort and
had one of the three designated diagnoses upon entry into the
cohort, we do not know how many other veterans received
SCS implants but were not included in this study or if they
developed additional MSDs following entry into the cohort.
We also do not know how many veterans received an SCS
implant outside of the VHA, even if the procedure was
authorized byVHA. Fourth, we could not reliably distinguish
between the coding of SCS trials vs implants. Fifth, the data
from this study are approximately 7 years old due to the
limits of the MSD cohort used for this study.33 Finally,
advances in SCS technology continue to be made, as well
as the claims of improved effectiveness of SCSs.23
Future research can extend these analyses by further
examining additional outcome variables available in the
EHR of veterans with SCS implants (eg, depressive dis-
order, use of non-opioid analgesics, use of the healthcare
system). For example, a future study could examine the
hypothesis of reduced healthcare utilization, improved
pain trajectory and associated costs of care following
SCS implantation. With the increasing use of EHR in
other public and private healthcare settings, the methods
used in this observational study could be applied to exam-
ine similar questions in other healthcare settings. It also
would be interesting to compare veterans, active duty
service members, and civilians to determine whether
demographic and clinical characteristics, facility character-
istics, and/or clinical outcomes differ among those groups.
Dovepress Wandner et al
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